These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

176 related articles for article (PubMed ID: 25025339)

  • 21. Target immobilization as a strategy for NMR-based fragment screening: comparison of TINS, STD, and SPR for fragment hit identification.
    Kobayashi M; Retra K; Figaroa F; Hollander JG; Ab E; Heetebrij RJ; Irth H; Siegal G
    J Biomol Screen; 2010 Sep; 15(8):978-89. PubMed ID: 20817886
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Fragment-Based and Structural Investigation for Discovery of JNK3 Inhibitors.
    Duong MTH; Ahn HC
    Pharmaceutics; 2022 Sep; 14(9):. PubMed ID: 36145648
    [TBL] [Abstract][Full Text] [Related]  

  • 23. In silico fragment-based drug design with SEED.
    Marchand JR; Caflisch A
    Eur J Med Chem; 2018 Aug; 156():907-917. PubMed ID: 30064119
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Ligand specificity in fragment-based drug design.
    Barelier S; Pons J; Gehring K; Lancelin JM; Krimm I
    J Med Chem; 2010 Jul; 53(14):5256-66. PubMed ID: 20575554
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Creating novel activated factor XI inhibitors through fragment based lead generation and structure aided drug design.
    Fjellström O; Akkaya S; Beisel HG; Eriksson PO; Erixon K; Gustafsson D; Jurva U; Kang D; Karis D; Knecht W; Nerme V; Nilsson I; Olsson T; Redzic A; Roth R; Sandmark J; Tigerström A; Öster L
    PLoS One; 2015; 10(1):e0113705. PubMed ID: 25629509
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Rapid protein-ligand costructures using chemical shift perturbations.
    Stark J; Powers R
    J Am Chem Soc; 2008 Jan; 130(2):535-45. PubMed ID: 18088118
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Multi-target Fragments Display Versatile Binding Modes.
    Drwal MN; Bret G; Kellenberger E
    Mol Inform; 2017 Oct; 36(10):. PubMed ID: 28691374
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Fragment based drug design: from experimental to computational approaches.
    Kumar A; Voet A; Zhang KY
    Curr Med Chem; 2012; 19(30):5128-47. PubMed ID: 22934764
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Binding Moiety Mapping by Saturation Transfer Difference NMR.
    Brender JR; Krishnamoorthy J; Ghosh A; Bhunia A
    Methods Mol Biol; 2018; 1824():49-65. PubMed ID: 30039401
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Applications of (19)F-NMR in Fragment-Based Drug Discovery.
    Norton RS; Leung EW; Chandrashekaran IR; MacRaild CA
    Molecules; 2016 Jul; 21(7):. PubMed ID: 27438818
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Parallel screening of low molecular weight fragment libraries: do differences in methodology affect hit identification?
    Wielens J; Headey SJ; Rhodes DI; Mulder RJ; Dolezal O; Deadman JJ; Newman J; Chalmers DK; Parker MW; Peat TS; Scanlon MJ
    J Biomol Screen; 2013 Feb; 18(2):147-59. PubMed ID: 23139382
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Small molecules bound to unique sites in the target protein binding cleft of calcium-bound S100B as characterized by nuclear magnetic resonance and X-ray crystallography.
    Charpentier TH; Wilder PT; Liriano MA; Varney KM; Zhong S; Coop A; Pozharski E; MacKerell AD; Toth EA; Weber DJ
    Biochemistry; 2009 Jul; 48(26):6202-12. PubMed ID: 19469484
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Fragment-based screening using X-ray crystallography and NMR spectroscopy.
    Jhoti H; Cleasby A; Verdonk M; Williams G
    Curr Opin Chem Biol; 2007 Oct; 11(5):485-93. PubMed ID: 17851109
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Overview of Probing Protein-Ligand Interactions Using NMR.
    Aguirre C; Cala O; Krimm I
    Curr Protoc Protein Sci; 2015 Aug; 81():17.18.1-17.18.24. PubMed ID: 26237672
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [NMR screening in fragment-based drug discovery].
    Hanzawa H; Takizawa T
    Yakugaku Zasshi; 2010 Mar; 130(3):325-33. PubMed ID: 20190517
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A Step toward NRF2-DNA Interaction Inhibitors by Fragment-Based NMR Methods.
    Brüschweiler S; Fuchs JE; Bader G; McConnell DB; Konrat R; Mayer M
    ChemMedChem; 2021 Dec; 16(23):3576-3587. PubMed ID: 34524728
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A fragment-based approach to discovery of Receptor for Advanced Glycation End products inhibitors.
    Kozlyuk N; Gilston BA; Salay LE; Gogliotti RD; Christov PP; Kim K; Ovee M; Waterson AG; Chazin WJ
    Proteins; 2021 Nov; 89(11):1399-1412. PubMed ID: 34156100
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Performance of protein-ligand docking with simulated chemical shift perturbations.
    Ten Brink T; Aguirre C; Exner TE; Krimm I
    J Chem Inf Model; 2015 Feb; 55(2):275-83. PubMed ID: 25357133
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The rise of molecular simulations in fragment-based drug design (FBDD): an overview.
    Bissaro M; Sturlese M; Moro S
    Drug Discov Today; 2020 Sep; 25(9):1693-1701. PubMed ID: 32592867
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Structure-guided fragment-based drug discovery at the synchrotron: screening binding sites and correlations with hotspot mapping.
    Thomas SE; Collins P; James RH; Mendes V; Charoensutthivarakul S; Radoux C; Abell C; Coyne AG; Floto RA; von Delft F; Blundell TL
    Philos Trans A Math Phys Eng Sci; 2019 Jun; 377(2147):20180422. PubMed ID: 31030650
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.